Posted August 5, 2014 by & filed under Australian Commercial Doors, Case Study.

Tuesday, August 5, 2014

Australian Biotechnology Manufacturing FacilityCSL Limited officially opened the CSL Behring Biotechnology Manufacturing Facility in Broadmeadows, Melbourne in May 2014 and is gearing up to begin production in August. The facility was officially opened by The Hon. Ian Macfarlane MP, Minister for Industry, The Hon. Denis Napthine MP, Premier of Victoria and The Hon. Gordon Rich-Phillips MLC, Minister for Technology, Victoria.

The new world-class facility is located adjacent to CSL Behring’s manufacturing plant for plasma products and will play a key role in CSL’s global drug development strategy. It is one of the largest and most advanced facilities of its kind in Australia and will produce novel recombinant therapies on a large scale for international clinical trials.

The biotech facility is the centre-piece of a $257 million manufacturing expansion at the Broadmeadows site which will see it play an increasingly important role in CSL’s global operations. The total investment is expected to quadruple Broadmeadows’ manufacturing capacity and export potential by 2018 and generate more than 240 highly skilled jobs.

In total, over 20 Efaflex High Speed Doors were supplied by Premier Doors for the project. The Efaflex Specialty High Speed Clean Room Door was used throughout the CSL Behring facility to provide a level of compliance and hygiene control that is vital in a manufacturing facility such as this. The Efaflex SRT-CR High Speed Door is perfectly suited to this application due to its Stainless Steel construction and near Air-Tight sealing. This high performance door has smooth surfaces and no protruding edges, making them easy to clean and eliminates the gathering of particle deposits. The GMP-compatible door also conforms to international standards and guidelines for clean room applications.

Speaking at the Opening, CSL’s CEO and Managing Director, Paul Perreault said “This world-class facility is key to the ongoing success of our global R&D strategy and reflects our commitment to provide better treatment options for people who suffer from bleeding disorders and other life-threatening conditions.”

Click here to learn more about the Efaflex – Clean Room High Speed Door


CSL Opens Australian Biotechnology Manufacturing Facility

Melbourne, Australia — 09/05/2014